

Boston Scientific Announces Collaborations on Cardiovascular Imaging Technology With Philips and Siemens

Company's iLab® Ultrasound Imaging System compatible with leading X-ray systems

NATICK, Mass., May 24 [/PRNewswire-FirstCall/](#) -- Boston Scientific Corporation (NYSE: BSX) today announced collaborations with Philips Healthcare and Siemens Medical Solutions to enable the use of its iLab® Ultrasound Imaging System with the Philips Allura™ Xper and the Siemens AXIOM™ Artis and Artis™ zee interventional X-ray systems. Intravascular ultrasound (IVUS) technology is designed to provide physicians a 360-degree view inside the heart and coronary vessels to assist with diagnosis and to generate a more accurate image of the diseased vessels than is possible with angiography alone.

Boston Scientific's collaborations with Philips and Siemens include recently completed compatibility testing, which confirmed that the iLab System can function as an integrated system with the Philips and Siemens X-ray systems. The Company previously announced a similar collaboration with GE Healthcare and its Innova® System. The iLab System is designed to be installed directly into a cardiac catheterization laboratory or radiology suite alongside these X-ray systems, enabling physicians to more readily incorporate IVUS technology into their procedures. The integrated systems will be featured at the annual EuroPCR Scientific Program, May 25 – 28 in Paris.

"Boston Scientific is proud to work with Philips and Siemens to offer integrated imaging systems that support improvements in performance, workflow and ease of use," said Joe Fitzgerald, Senior Vice President and President of Boston Scientific's Endovascular Unit. "Cath labs worldwide can now integrate the iLab Ultrasound Imaging System with the vast majority of interventional X-ray systems."

IVUS technology incorporates a tiny catheter inserted into the heart or coronary vessels where high-frequency sound waves reflect off tissue or vessel walls. The reflected sound waves create a cross-sectional image from within the heart or vessel, which can help determine treatment options. Unlike fractional flow reserve (FFR) technology, IVUS may be used to help select balloon and stent sizes and to view stent apposition and expansion after stent placement. The iLab System features exceptional image quality and the option for physicians to use a variety of catheters to accommodate coronary, peripheral and intracardiac echocardiography (ICE) applications.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our financial performance, product performance, significance of event data, competitive offerings, our market position and our growth strategy. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – *Risk Factors* in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – *Risk Factors* in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is

applicable to all forward-looking statements contained in this document.

CONTACT: Paul Donovan
508-650-8541 (office)
508-667-5165 (mobile)
Media Relations
Boston Scientific Corporation

Larry Neumann
508-650-8696 (office)
Investor Relations
Boston Scientific Corporation

SOURCE Boston Scientific Corporation

<https://news.bostonscientific.com/news-releases?item=59241>